{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:38:30Z","timestamp":1791319110372,"version":"4.3.1"},"reference-count":31,"publisher":"American Society for Microbiology","issue":"3","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2014,3]]},"abstract":"ABSTRACT<\/jats:title>\n \n The activities of the novel \u03b2-lactam\u2013\u03b2-lactamase inhibitor combination ceftazidime-avibactam and comparator agents were evaluated against a contemporary collection of clinically significant Gram-negative bacilli. Avibactam is a novel non-\u03b2-lactam \u03b2-lactamase inhibitor that inhibits Ambler class A, C, and some D enzymes. A total of 10,928 Gram-negative bacilli\u20148,640\n Enterobacteriaceae<\/jats:named-content>\n , 1,967\n Pseudomonas aeruginosa<\/jats:named-content>\n , and 321\n Acinetobacter<\/jats:named-content>\n sp. isolates\u2014were collected from 73 U.S. hospitals and tested for susceptibility by reference broth microdilution methods in a central monitoring laboratory (JMI Laboratories, North Liberty, IA, USA). Ceftazidime was combined with avibactam at a fixed concentration of 4 \u03bcg\/ml. Overall, 99.8% of\n Enterobacteriaceae<\/jats:named-content>\n strains were inhibited at a ceftazidime-avibactam MIC of \u22644 \u03bcg\/ml. Ceftazidime-avibactam was active against extended-spectrum \u03b2-lactamase (ESBL)-phenotype\n Escherichia coli<\/jats:named-content>\n and\n Klebsiella pneumoniae<\/jats:named-content>\n , meropenem-nonsusceptible (MIC \u2265 2 \u03bcg\/ml)\n K. pneumoniae<\/jats:named-content>\n , and ceftazidime-nonsusceptible\n Enterobacter cloacae<\/jats:named-content>\n . Among ESBL-phenotype\n K. pneumoniae<\/jats:named-content>\n strains, 61.1% were meropenem susceptible and 99.3% were inhibited at a ceftazidime-avibactam MIC of \u22644 \u03bcg\/ml. Among\n P. aeruginosa<\/jats:named-content>\n strains, 96.9% were inhibited at a ceftazidime-avibactam MIC of \u22648 \u03bcg\/ml, and susceptibility rates for meropenem, ceftazidime, and piperacillin-tazobactam were 82.0, 83.2, and 78.3%, respectively. Ceftazidime-avibactam was the most active compound tested against meropenem-nonsusceptible\n P. aeruginosa<\/jats:named-content>\n (MIC\n 50<\/jats:sub>\n \/MIC\n 90<\/jats:sub>\n , 4\/16 \u03bcg\/ml; 87.3% inhibited at \u22648 \u03bcg\/ml).\n Acinetobacter<\/jats:named-content>\n spp. (ceftazidime-avibactam MIC\n 50<\/jats:sub>\n \/MIC\n 90<\/jats:sub>\n , 16\/>32 \u03bcg\/ml) showed high rates of resistance to most tested agents. In summary, ceftazidime-avibactam demonstrated potent activity against a large collection of contemporary Gram-negative bacilli isolated from patients in U.S. hospitals in 2012, including organisms that are resistant to most currently available agents, such as\n K. pneumoniae<\/jats:named-content>\n carbapenemase (KPC)-producing\n Enterobacteriaceae<\/jats:named-content>\n and meropenem-nonsusceptible\n P. aeruginosa<\/jats:named-content>\n .\n <\/jats:p>","DOI":"10.1128\/aac.02429-13","type":"journal-article","created":{"date-parts":[[2013,12,31]],"date-time":"2013-12-31T02:28:14Z","timestamp":1388456894000},"page":"1684-1692","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":115,"title":["Antimicrobial Activity of Ceftazidime-Avibactam against Gram-Negative Organisms Collected from U.S. Medical Centers in 2012"],"prefix":"10.1128","volume":"58","author":[{"given":"Helio S.","family":"Sader","sequence":"first","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Castanheira","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert K.","family":"Flamm","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Farrell","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald N.","family":"Jones","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks460"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.12010"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199447030-00008"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.12023"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.2012.0238"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.05035-11"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1574-6976.2011.00268.x"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mib.2011.07.026"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2013.03.032"},{"key":"e_1_3_2_11_2","volume-title":"Approved standard","author":"Clinical and Laboratory Standards Institute","year":"2012","unstructured":"Clinical and Laboratory Standards Institute. 2012. M07-A9. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard, 9th ed. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"9"},{"key":"e_1_3_2_12_2","volume-title":"M100-S23. Performance standards for antimicrobial susceptibility testing","author":"Clinical and Laboratory Standards Institute","year":"2013","unstructured":"Clinical and Laboratory Standards Institute. 2013. M100-S23. Performance standards for antimicrobial susceptibility testing, 23rd informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"23"},{"key":"e_1_3_2_13_2","unstructured":"EUCAST. 2013. Breakpoint tables for interpretation of MICs and zone diameters. Version 3.1 February 2013. http:\/\/www.eucast.org\/clinical_breakpoints\/."},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02252-12"},{"key":"e_1_3_2_15_2","first-page":"108","article-title":"Hospital outbreak of carbapenem-resistant Klebsiella pneumoniae producing New Delhi metallo-beta-lactamase\u2014Denver, Colorado, 2012. MMWR Morb","volume":"62","author":"Pisney L","year":"2013","unstructured":"PisneyLBarronMJanelleSBambergWMacCannellDKallenAGouldCLimbagoBEpsonEWendtJ. 2013. Hospital outbreak of carbapenem-resistant Klebsiella pneumoniae producing New Delhi metallo-beta-lactamase\u2014Denver, Colorado, 2012. MMWR Morb. Mortal. Wkly. Rep. 62:108.","journal-title":"Mortal. Wkly. Rep."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01896-13"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit152"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1586\/eri.09.108"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2011.03570.x"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-103-4-552"},{"key":"e_1_3_2_21_2","first-page":"165","article-title":"Vital signs: carbapenem-resistant enterobacteriaceae","volume":"62","author":"Jacob JT","year":"2013","unstructured":"JacobJTKleinELaxminarayanRBeldavsZLynfieldRKallenAJRicksPEdwardsJSrinivasanAFridkinSRasheedKJLonswayDBulensSHerreraRMcDonaldLCPatelJLimbagoBBellMCardoD. 2013. Vital signs: carbapenem-resistant enterobacteriaceae. MMWR Morb. Mortal. Wkly. Rep. 62:165\u2013170.","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2012.03821.x"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tim.2011.04.005"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-198529020-00002"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02247-12"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-013-0013-7"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp197"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00756-10"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01198-10"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06064-11"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01696-10"},{"key":"e_1_3_2_32_2","volume-title":"Tygacil package insert","author":"Pfizer, Inc","year":"2012","unstructured":"Pfizer, Inc. 2012. Tygacil package insert. Pfizer, Inc., Philadelphia, PA. http:\/\/www.tygacil.com."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02429-13","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02429-13","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T22:38:32Z","timestamp":1645483112000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02429-13"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["10.1128\/AAC.02429-13"],"URL":"https:\/\/doi.org\/10.1128\/aac.02429-13","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3]]},"assertion":[{"value":"2013-11-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-12-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-02-19","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}